,32 In parallel, DLBCL is characterized by frequent epigenetic aberrations, with a substantial subset of patients (25%) harboring loss-of-function mutations in genes encoding key histone acetyltransferases, such as CREBBP and EP300. 33,34 These insights underscore the rationale for incorporating epigenetic therapies into DLBCL regimens, particularly in the context of HBV coinfection. The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.